Inflammatory Bowel Disease | Crohn's Disease and IBD Early Treatment Response

Watch and understand how Inflammatory Bowel Diseases, such as Crohn's, can benefit from biomarkers in drug development.
This presentation was presented by Joachim Høg Mortensen, PhD, at the ECM Symposium 2021 organized by Nordic Bioscience.
Dr. Mortensen has extensive research experience in the field of gastroenterology, and more specifically Inflammatory Bowel Disease (IBD). In collaboration with Nordic Bioscience Dr. Mortensen focused his Ph.D. research on the development and validation of serum-based biochemical markers for IBD in relation to intestinal mucosal damage, by quantifying the degree of basement membrane degradation and interstitial matrix remodeling with highly specific serum-based ELISA’s, and joined Nordic Bioscience in 2016 assuming a position as Senior Scientist in the ImmunoScience-IBD group.
The main focus of his research group is on the development of blood-based biomarkers to quantify the degree of tissue-related Inflammation and mucosal damage in IBD patients. Dr. Mortensen has spearheaded the development of a biomarker of human neutrophil elastase degraded calprotectin (CPa9-HNE), a novel serum calprotectin that is a biomarker of true neutrophil activity. Dr. Mortensen has been supervising master students and technicians alike and is currently supervising three PhD projects related to IBD biomarker development for mucosal healing, intestinal fibrosis and intestinal inflammation.
20+ publications in peer-reviewed journals; Mortensen@Pubmed 463 citations, H-factor: 10, 140 citations/year, Ph.D. students mentored: 3.
For more information, please visit our website: www.nordicbioscience.com
Or contact us: www.nordicbioscience.com/contact
***
Nordic Bioscience is the leading expert in extracellular matrix (ECM) research with 25+ years of experience in biomarker development, pre-clinical and clinical research. With more than 550 peer-reviewed publications, our science-driven approach has been the evolving force behind our decades of success.
Through our Protein Fingerprint technology, we identify fragments of the ECM that are released from affected tissues and develop blood-based biomarker assays to quantify disease activity with the aim of precision medicine.
By quantifying tissue remodeling, our biomarkers provide true prognostic and predictive value, as we can select the patients who are most likely to respond to a given treatment and thereby function as surrogate biomarkers for clinical trials. Our biomarker assays not only enable faster drug development but also improve disease outcomes for chronically ill patients by predicting treatment response.
Nordic Bioscience is headquartered in Herlev, Denmark, with a high-quality standard laboratory, running clinical trials under Good Clinical Laboratory Practice (GCLP) with accreditation by the College of American Pathologists (CAP) and ISO9001 certificate. Everything in our laboratory supports compliance to FDA 21 CFR Part 11. We employ more than 180 people who are dedicated to improving patient management for a broad range of therapeutic areas including Hepatology, Rheumatology, Dermatology, Oncology, Gastroenterology, Respiratory, Neurodegenerative and Cardiovascular diseases.
Follow us on our other social media channels to stay informed on the latest news of cutting-edge biomarker research!
LinkedIn: / nordicbioscience
Twitter: / nordic_bio
#nordicbioscience #lifescience #gastrointestinal #IBD #Crohns #fibrosis #biomarkers #proteinfingerprint #webinar #extracellularmatrix #ecm